Abstracts tagged "Cardiovascular"

Abstract Number: 0856 • ACR Convergence 2024
Comparative Effectiveness of Disease Modifying Antirheumatic Drugs for Cardiac Sarcoidosis
Michael Putman¹, Lisbeth Brooks², William Kivlin², Divyanshu Mohananey² and Viktoriya Sabchyshyn², ¹The Medical College of Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: No studies to date have evaluated the comparative efficacy of disease modifying antirheumatic drugs (DMARDs) for cardiac sarcoidosis. Methods: We performed a retrospective cohort…
Abstract Number: 1345 • ACR Convergence 2024
Long-term Changes in Coronary Calcium Score Levels Among Patients with Rheumatoid Arthritis: A Cohort Study
Cristina Corrales Selaya¹, Nuria Vegas Revenga², Carmen Secada Gómez³, Jose Antonio parra-Blanco⁴, Virginia Portilla-González⁴, Ricardo Blanco-Alonso⁵, Miguel Angel Gonzalez-Gay⁶, ivan Ferraz-Amaro⁷ and alfonso Corrales-Martínez⁸, ¹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ²Hospital Galdakao- Usansolo, Galdakao, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁶University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of subclinical cardiovascular (CV) disease and, consequently, a higher incidence of CV events, compared to the…
Abstract Number: 1615 • ACR Convergence 2024
Is Regular Vascular Imaging Scheduled Essential in the Follow-Up of Takayasu Arteritis? A Large-Scale Multicenter Cohort Study
Fatih Yildirim¹, Cemal Bes², Muhammet Emin Kutu³, Fatih Tastekin⁴, Gokhan Keser⁵, Tugba Ocak⁶, Ediz Dalkilic⁶, Yavuz Pehlivan⁶, Hasan Kocaayan⁷, Servet Akar⁷, Sema İsik⁸, Ahmet Omma⁹, Senar San¹⁰, Ayten Yazici¹¹, Ayse Cefle¹¹, Safiye Bakkal¹², Gökçe Kenar¹³, Fatos Onen¹², Aysegül Avcu¹⁴, Fatma Alibaz Öner¹⁵, Haner Direskeneli¹⁵, Burcu Ceren Uludogan¹⁶, Nazife Sule yaşar Bile¹⁶ and Nilüfer Alpay Kanıtez¹⁷, ¹University of Health Sciences Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey, İstanbul, Turkey, ²University of Health Sciences Başakşehir Çam and Sakura City HospitalUniversity of Health Sciences Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey, İstanbul, Turkey, ³Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁴Ege University School of Medicine, Rheumatology, İzmir, Turkey, İzmir, Turkey, ⁵Ege University School of Medicine, Rheumatology, İzmir, Turkey, Izmir, Turkey, ⁶Uludağ University Faculty of Medicine, Rheumatology, Bursa, Turkey, Bursa, Turkey, ⁷İzmir Katip Celebi University School of Medicine, Rheumatology, İzmir, Turkey, İzmir, Turkey, ⁸University of Health Sciences Ankara Bilkent City Hospital, Rheumatology, Ankara, Turkey, Ankara, Turkey, ⁹Ankara Bilkent City Hospital, Ankara, Turkey, ¹⁰Kocaeli University Faculty of Medicine, Rheumatology, Kocaeli, Turkey, Kocaeli, Turkey, ¹¹Kocaeli University Faculty of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ¹²Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, İzmir, Turkey, ¹³Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁴Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, İstanbul, Turkey, ¹⁵Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey, ¹⁶Osmangazi University Faculty of Medicine, Rheumatology, Eskişehir, Turkey, Eskisehir, Turkey, ¹⁷Koc University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey
Background/Purpose: The understanding of progression or minimal disease activity in patients with Takayasu arteritis (TA) can be complicated due to the possibility of mild vascular…
Abstract Number: 2216 • ACR Convergence 2024
Additive Impact of Rheumatoid Arthritis and HBcAb+ on All-cause and Cardiovascular Mortality
Leiyi Yang¹, Bo Chen², Qibing Xie³ and Geng Yin⁴, ¹Sichuan University, Cheng Du Shi, Sichuan, China (People's Republic), ²Chenbo, Chendu, Sichuan, China, ³Department of Rheumatology and Immunology, Chengdu, Sichuan, China, ⁴Department of Rheumatology and Immunology, chengdu, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) and hepatitis B both have a high incidence and significant health impacts, possibly sharing a pathogenic connection. Notably, a considerable proportion of…
Abstract Number: 2510 • ACR Convergence 2024
The Effect of Coronary Artery Aneurysms and IVIG Use on Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis
Francis Lao¹, Cal Robinson², Dorota Borovski³, KAREN BEATTIE⁴, Joycelyne Ewusie⁵, Rahul Chanchlani³ and Michelle Batthish⁶, ¹The Hospital for Sick Children, Hamilton, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³McMaster University, Hamilton, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵McMaster University, Hamilton, ⁶McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: Kawasaki Disease (KD) is a common childhood vasculitis. Coronary artery aneurysms (CAAs) develop in approximately 25% of untreated KD patients. However, there is limited…
Abstract Number: 0205 • ACR Convergence 2024
Cardiovascular Event Risks Among Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: A growing body of evidence highlights a link between rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE)…
Abstract Number: 0540 • ACR Convergence 2024
Nonsteroidal Anti-Inflammatory Drug Use and Incident Hypertension Among Patients with Axial Spondyloarthritis
Jose Meade Aguilar¹, Jean Liew², Rachael Stovall³, Sofia Ramiro⁴ and Lianne S Gensler⁵, ¹Boston Medical Center, Boston, MA, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³University of Washington, Seattle, ⁴Leiden University Medical Center, Bunde, Netherlands, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Patients with axial spondyloarthritis (axSpA) have a heightened risk of cardiovascular morbidity and mortality. Nonsteroidal anti-inflammatory drugs (NSAIDs) are first line treatment for axSpA,…
Abstract Number: 0857 • ACR Convergence 2024
Exploring Clinical Outcomes of Patients with Cardiac Sarcoidosis on TNF Inhibitors: A Nationwide Retrospective Cohort Study
Yurilu Gonzalez Moret¹, Diego Lema² and Fabian Rodriguez Quinonez³, ¹Jefferson Einstein Hospital, Philadelphia, PA, ²Universidad Central de Venezuela, University of Wisconsin, Philadelphia, PA, ³Einstein Medical Center Philadelphia, Philadelphia, PA
Background/Purpose: Immunosuppressive therapy, including Tumor necrosis factor inhibitors (TNFi), is commonly used in the treatment of various inflammatory conditions, including extracardiac sarcoidosis. However, the use…
Abstract Number: 1347 • ACR Convergence 2024
Interest of DAS28-γGT in Assessing Cardiovascular Risk Activity in Rheumatoid Arthritis in Routine Practice
Manon Lesturgie-Talarek¹, Fabien Picard², sabrina hamroun³, Malika Saadi², Camille Macher⁴, Aude Deloumeau³, Karim Wahbi², jacques Blacher⁴, Yannick Allanore⁵ and Jérôme Avouac⁶, ¹Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ²Cardiology Department - Cochin Hospital, Paris, France, ³Rheumatology Department - Cochin Hospital, Paris, France, ⁴Cardiology Department, Hôtel Dieu Hospital, Paris, France, ⁵Université Paris Cité, Paris, France, ⁶Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular (CV) mortality, linked to systemic inflammation and the presence of associated CV risk factors.…
Abstract Number: 1719 • ACR Convergence 2024
Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis: A Nested Case-Control Study
Beth Wallace¹, Yuqing Gao², H. Myra Kim³, Bryant England⁴, Sauer brian⁵, grant Cannon⁶, Punyasha Roul⁷, Ted Mikuls⁴, Shirley Cohen-Mekelburg⁸, Daniel Clauw⁹, Wyndy Wiitala², Rodney Hayward¹⁰, Jeremy Sussman¹¹ and Akbar Waljee¹¹, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³University of Michigan School of Public Health, Ann Arbor, MI, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸University of Michigan Department of Internal Medicine, Division of Gastroenterology, Ann Arbor, MI, ⁹University of Michigan, Whitmore Lake, MI, ¹⁰Department of Internal Medicine, University of Michigan; Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI, ¹¹Internal Medicine and Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Our work presented previously suggests recent GC use (up to 2 years prior…
Abstract Number: 2230 • ACR Convergence 2024
Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis
Maria Garcia-Gonzalez¹, Fuensanta Gomez-Bernal², Juan Carlos Quevedo-Abeledo³, Miguel Angel Gonzalez-Gay⁴ and ivan Ferraz-Amaro⁵, ¹Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: The complement system has been linked to the etiopathogenesis of rheumatoid arthritis (RA). Patients with RA exhibit a dysregulated profile of lipid molecules, which…
Abstract Number: 2576 • ACR Convergence 2024
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
April Jorge¹, Aakash Patel¹, Baijun Zhou², Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are hypoglycemic agents with well-established cardioprotective properties and emerging data for kidney-protective benefits in patients with type 2 diabetes…
Abstract Number: 0215 • ACR Convergence 2024
BP Connect Improves Follow-up of High Blood Pressure in Urban Rheumatology and Non-Rheumatology Clinics
Alexa Figueroa Baiges¹, David Gazeley², Monica Messina¹, Bret Hanlon³, Edmond Ramly⁴, Ann Rosenthal⁵, Laura Stewart⁶, Makeba Williams⁷, Heidi W. Brown⁸ and Christie Bartels⁹, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Medical College of Wisconsin, Wauwatosa, WI, ³Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Indiana University School of Public Health, Bloomington, IN, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Froedtert and Medical College of Wisconsin, Milwaukee, WI, ⁷Washington University in St. Louis School of Medicine, St. Louis, MO, ⁸Division of Health Services Research & Implementation Science, Kaiser Permanente, San Diego, CA, ⁹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hypertension accounts for >54% of modifiable cardiovascular disease (CVD) risk and although 49% of US outpatient visits occur in specialty clinics, only 10% of…
Abstract Number: 0598 • ACR Convergence 2024
Cardio-metabolic Effects of Apremilast in Patients with Psoriatic Arthritis: A Prospective Cohort Study
Eva van Geel¹, Romy Hansildaar², Fatih Çoban¹, Bas Dijkshoorn¹, Maaike Heslinga¹, Reinhard Bos³, Mies Korteweg¹, Arno Van Kuijk¹ and Michael Nurmohamed⁴, ¹Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Reade and Amsterdam UMC, Kortenhoef, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is associated with metabolic and cardiovascular disease. Studies have suggested that treatment with apremilast is associated with weight loss and other…
Abstract Number: 0870 • ACR Convergence 2024
The Impact of Body Mass Index on Cardiovascular Risk in Rheumatoid Arthritis Varies Across Anticitrullinated Protein Antibody Status and Biologic Use
George Karpouzas¹, Elena Myasoedova², Miguel Angel Gonzalez-Gay³, alfonso Corrales-Martínez⁴, Solbritt Rantapaa-Dahlqvist⁵, Petros Sfikakis⁶, Patrick Dessein⁷, Linda Tsang⁸, Carol Hitchon⁹, Hani El Gabalawy¹⁰, Virginia Pascual Ramos¹¹, Irazu Contreras Yanez¹², Iris Jazmín Colunga Pedraza¹³, Dionicio Galarza-Delgado¹⁴, jose Ramon Azpiri-Lopez¹⁵, Anne Grete Semb¹⁶, Piet Van RIel¹⁷, Durga P Misra¹⁸, Patrick Durez¹⁹, Brian Bridal Logstrup²⁰, Ellen Margrethe Hauge²¹, George Kitas²² and Sarah Ormseth²³, and An inTernationAl Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA), ¹Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA, ²Mayo Clinic, Rochester, MN, ³University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Umeå University, Umeå, Sweden, ⁶Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁷University of Witwatersrand, Johannesburg, South Africa, ⁸University of Witwatersrand, Johanessburg, South Africa, ⁹University of Mannitoba, Winnipeg, Canada, ¹⁰University of Mannitoba, Winnipeg, MB, Canada, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ¹²Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ¹⁵Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁶Diakonhjemmet Hospital, Oslo, Norway, ¹⁷Radboud University Medical Center, Nijmegen, Netherlands, ¹⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁹UCLouvain, Louvain, Belgium, ²⁰University of Aarhus, Aarhus, Denmark, ²¹Aarhus Universitetshospital, Aarhus, Denmark, ²²The Dudley Group NHS, Birmingham, United Kingdom, ²³The Lundquist Institute, Torrance, CA
Background/Purpose: The impact of body mass index (BMI) as a surrogate of body fat content on cardiovascular (CV) risk in rheumatoid arthritis (RA) is unclear.…

« Previous Page
1
…
4
5
6
7
8
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].